Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersGastroenterology Physician in Boston, MA
NPI: 1447328711Primary Practice Location
Boston Food Allergy Center LLC Bi Network
1 Nassau St, Boston, MA
Primary Employer
Boston Food Allergy Center LLC Bi Network
bostonspecialists.org
HQ Phone
Get M.D. John's Phone NumberMobile
Get M.D. John's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 65 | 146 |
| 2 | 99204New patient office or other outpatient visit, 45-59 minutes | 57 | 57 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 30 | 46 |
| 4 | 43239Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | 13 | 13 |
Discovery of an agonistic Siglec-6 antibody that inhibits and reduces human mast cells.
Authors: Schanin, Julia, Korver, Wouter, Brock, Emily C, Leung, John, Benet, Zachary, Luu, Thuy, Chang, Katherine, Xu, Alan, De Freitas, Naomi, Luehrsen, Kenneth, Brehm, Michael A, Wong, Alan, Youngblood, Bradford A
Journal: Commun Biol
Publication Date: 2022-11-11
Eosinophilic Esophagitis Patients Are Not at Increased Risk of Severe COVID-19: A Report From a Global Registry.
Authors: Mirna Chehade
Publication Date: 2021-08-11
IgE-mediated hypersensitivity to ondansetron and safe use of palonosetron.
Authors: Autumn Guyer, Aleena Banerji
Journal: J Allergy Clin Immunol Pract
Publication Date: 2013-06-25
Lead Sponsor: Shire
Intervention / Treatment: DRUG: Placebo, DRUG: Oral Budesonide Suspension (OBS)
Lead Sponsor: Children's Hospital Medical Center, Cincinnati
Collaborators: National Institutes of Health (NIH), Regeneron Pharmaceuticals
Intervention / Treatment: DRUG: Placebo (blinded), DRUG: Dupilumab (blinded), DRUG: Dupilumab (open-label)
Lead Sponsor: Children's Hospital Medical Center, Cincinnati
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), National Center for Advancing Translational Sciences (NCATS), Office of Rare Diseases (ORD)
